Anaplastic lymphoma kinase (ALK)-positive lymphomas respond to chemotherapy, but relapses, which bear a poor prognosis, occur. Crizotinib inhibits ALK in vitro and in vivo and was administered as monotherapy to 11 ALK+ lymphoma patients who were resistant/refractory to cytotoxic therapy. The overall response rate was 10 of 11 (90.9%; 95% confidence interval [CI] = 58.7% to 99.8%). Disease status at the latest follow-up is as follows: four patients are in complete response (CR) (months >21, >30, >35, >40) under continuous crizotinib administration; 4 patients had progression of disease (months 1, 2, 2, 2); 1 patient obtained CR on crizotinib, received an allogeneic bone marrow transplant, and is in CR; 2 patients (treated before and/or after allogeneic bone marrow transplant) obtained and are still in CR but they have stopped crizotinib. Overall and progression-free survival rates at 2 years are 72.7% (95% CI = 39.1% to 94.0%) and 63.7% (95% CI = 30.8% to 89.1%), respectively. ALK mutations conferring resistance to crizotinib in vitro could be identified in relapsed patients. Crizotinib exerted a potent antitumor activity with durable responses in advanced, heavily pretreated ALK+ lymphoma patients, with a benign safety profile.

GAMBACORTI PASSERINI, C., Farina, F., Stasia, A., Redaelli, S., Ceccon, M., Mologni, L., et al. (2014). Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106(2), 1-4 [10.1093/jnci/djt378].

Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients

GAMBACORTI PASSERINI, CARLO;REDAELLI, SARA;CECCON, MONICA;MOLOGNI, LUCA;MESSA, MARIA CRISTINA;Guerra, L;ANTOLINI, LAURA;PIAZZA, ROCCO GIOVANNI
2014

Abstract

Anaplastic lymphoma kinase (ALK)-positive lymphomas respond to chemotherapy, but relapses, which bear a poor prognosis, occur. Crizotinib inhibits ALK in vitro and in vivo and was administered as monotherapy to 11 ALK+ lymphoma patients who were resistant/refractory to cytotoxic therapy. The overall response rate was 10 of 11 (90.9%; 95% confidence interval [CI] = 58.7% to 99.8%). Disease status at the latest follow-up is as follows: four patients are in complete response (CR) (months >21, >30, >35, >40) under continuous crizotinib administration; 4 patients had progression of disease (months 1, 2, 2, 2); 1 patient obtained CR on crizotinib, received an allogeneic bone marrow transplant, and is in CR; 2 patients (treated before and/or after allogeneic bone marrow transplant) obtained and are still in CR but they have stopped crizotinib. Overall and progression-free survival rates at 2 years are 72.7% (95% CI = 39.1% to 94.0%) and 63.7% (95% CI = 30.8% to 89.1%), respectively. ALK mutations conferring resistance to crizotinib in vitro could be identified in relapsed patients. Crizotinib exerted a potent antitumor activity with durable responses in advanced, heavily pretreated ALK+ lymphoma patients, with a benign safety profile.
Articolo in rivista - Articolo scientifico
Lymphoma Patients
English
2014
106
2
1
4
djt378
none
GAMBACORTI PASSERINI, C., Farina, F., Stasia, A., Redaelli, S., Ceccon, M., Mologni, L., et al. (2014). Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106(2), 1-4 [10.1093/jnci/djt378].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/50872
Citazioni
  • Scopus 212
  • ???jsp.display-item.citation.isi??? 183
Social impact